Beijing Advaccine Biotechnology’s License agreement With INOVIO Pharmaceuticals Inc.


Sidley Austin LLP advised Beijing Advaccine Biotechnology Co. on the deal.

Beijing Advaccine Biotechnology Co., Ltd. (Advaccine) entered into a collaboration and license agreement with INOVIO Pharmaceuticals Inc. (NASDAQ: INO) (INOVIO) for COVID-19 DNA vaccine candidate INO-4800.

Advaccine is an emerging biotech company with next-generation technology in vaccines, both preventive and therapeutic. INOVIO is a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer.

Under the collaboration and license agreement, Advaccine will have the exclusive right to develop, manufacture, and commercialize INO-4800 within Greater China, inclusive of Mainland China, Hong Kong, Macao, and Taiwan. Advaccine will license its plasmid manufacturing process for use with INO-4800 and other INOVIO pipeline product candidates to INOVIO. Additionally, Advaccine will provide its clinical data to INOVIO in support of INOVIO’s global INO-4800 regulatory filings, and INOVIO will provide its INO-4800 clinical data for Advaccine to incorporate into its marketing applications in Greater China.

The Sidley team was led by partner Mengyu Lu (Picture) and senior counsel Chen Yang, with support from legal manager Ashlee Wu.

Involved fees earner: Mengyu Lu – Sidley Austin LLP; Chen Yang – Sidley Austin LLP;

Law Firms: Sidley Austin LLP;

Clients: Advaccine Biotechnology Co.;

Author: Michael Patrini